Why ITD 2025 matters for translation
Innovative Therapies Days 2025 (Besançon, October 9–10) brings together scientists, clinicians, and industry leaders working to turn advanced cell and gene therapy concepts into clinical and industrial reality. With sessions dedicated to Research → Proof of Concept, Proof → Clinic, Early-Stage Trials, and Scale-Up & Go-to-Market, the event is a practical forum where science meets production.
This year, Cellura joins the discussion to share how its technology enables a new generation of scalable, low-shear cell-culture systems that make fragile-cell manufacturing faster, safer, and more reproducible.
From lab to clinic — making sensitive cells scalable and reproducible
Transitioning from research to clinical-grade production remains a critical bottleneck in cell therapy. Cellura directly addresses this challenge through a geo-inspired, patented mixing technology that mimics the Earth’s rotation to generate chaotic yet ultra-gentle flow — completely bladeless, maintaining 12- to 50-fold lower shear forces than conventional stirred-tank systems.
Key advantages for experts and developers:
Viability & Function: protects iPSCs, immune cells, and organoids while ensuring robust proliferation.
Homogeneity & Reproducibility: optimized mass transfer and uniform conditions across the culture vessel.
True Scalability: identical parameters from 125 mL to industrial volumes, preserving process integrity.
Flexibility: compatible with microcarriers, aggregates, or single-cell suspension.
Ease of Integration: compact, incubator-ready, and GMP-friendly design that simplifies tech transfer.
Validated results include a 100-fold expansion of iPSCs in 7 days (>99% stemness), 10-fold expansion of NK cells, and functional organoid formation within 15 days — illustrating the platform’s versatility and reproducibility across applications.
Connecting science, technology, and clinical impact
Among the speakers at ITD 2025 are Dr Sjoukje van der Stegen (CZ Biohub, iPSC-derived immune cells), Prof Danièle Noël and Dr Farida Djouad (IRMB, MSC-derived EVs and cartilage repair), Prof Dominique Farge-Bancel (AP-HP, CAR-T for autoimmune diseases), Prof Sai Kiang Lim (Paracrine Therapeutics, exosome therapy), Dr Hélène Nègre (Cell for Cure by Seqens, ATMP release), Prof Erika Lietzan (University of Missouri, ATMP regulation), Dr Rahul Purwar (ImmunoACT, CAR-T in India), and Dr Claire Roddie (Autolus, adult ALL).
Their insights mirror Cellura’s mission: to build the technological bridge between cell biology, bioengineering, and therapeutic manufacturing.
Meet us at Booth #22 — let’s build tomorrow’s cell therapies together
Cellura will be present at Booth #22 in the Exhibitors’ Village throughout the event.
Our team will be pleased to welcome scientists, clinicians, and industrial partners to discuss ongoing and future collaborations. We will showcase our SoftXS™ bioreactor, share live data and demonstrations, and explore opportunities for joint scientific programs, pilot evaluations, and technology transfer.
Let’s connect in Besançon — and together, make scalable, high-quality cell manufacturing a reality for patients.
If you would like to arrange a discussion with our team during the event, please contact us at our short contact form.
We look forward to engaging with the community at
